Quantbot Technologies LP Buys New Stake in Elevance Health, Inc. $ELV

Quantbot Technologies LP purchased a new position in shares of Elevance Health, Inc. (NYSE:ELV) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 18,616 shares of the company’s stock, valued at approximately $6,015,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Physician Wealth Advisors Inc. lifted its stake in Elevance Health by 331.6% during the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares during the last quarter. Activest Wealth Management increased its stake in Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares during the last quarter. Rossby Financial LCC raised its holdings in Elevance Health by 110.0% during the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after purchasing an additional 44 shares in the last quarter. Vermillion & White Wealth Management Group LLC lifted its position in shares of Elevance Health by 94.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after buying an additional 37 shares during the last quarter. Finally, BOK Financial Private Wealth Inc. purchased a new stake in shares of Elevance Health during the 2nd quarter worth approximately $32,000. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Stock Down 0.7%

ELV opened at $320.65 on Friday. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75. The business has a 50 day moving average price of $350.23 and a two-hundred day moving average price of $335.70. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The company has a market cap of $70.77 billion, a PE ratio of 12.76, a P/E/G ratio of 1.77 and a beta of 0.50.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. During the same quarter in the previous year, the company posted $3.84 earnings per share. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, research analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be given a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is currently 27.23%.

Wall Street Analyst Weigh In

A number of research firms recently commented on ELV. TD Cowen reaffirmed a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Leerink Partners raised their price objective on Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a report on Thursday, January 29th. JPMorgan Chase & Co. lifted their target price on Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Royal Bank Of Canada downgraded Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price for the company. in a report on Tuesday, February 3rd. Finally, Guggenheim decreased their target price on Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a research report on Thursday, January 29th. Twelve research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $390.55.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.